Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies
Identifieur interne : 003165 ( Main/Corpus ); précédent : 003164; suivant : 003166Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies
Auteurs : Brigitte Piallat ; Abdelhamid Benazzouz ; Alim Louis BenabidSource :
- European Journal of Neuroscience [ 0953-816X ] ; 1996-07.
English descriptors
Abstract
Several studies have shown that antagonists of N‐methyl‐D‐aspartate receptors provide protection of the dopaminergic nigrostriatal pathway in animal models of Parkinson's disease. Since the substantia nigra compacta receives a moderate glutamatergic innervation from the subthalamic nucleus, we tried to determine whether subthalamic nucleus lesion could prevent the toxicity of the selective dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Experiments were carried out on four groups of rats. Group 1 (n= 10) received a unilateral injection of 6‐hydroxydopamine in the striatum and group 2 (n= 10) received kainic acid in the subthalamic nucleus. Group 3 (n= 10) received an injection of kainic acid in the subthalamic nucleus and 1 week later an injection of 6‐OHDA in the striatum. Group 4 (n= 5) received the same treatment but kainic acid was replaced by saline. Apomorphine induced an ipsilateral rotation in rats of groups 2 and 3 and a contralateral rotation in rats of groups 1 and 4. The number of tyrosine hydroxylase‐immunoreactive cells in the pars compacta of the substantia nigra was not significantly different between injected and non‐injected sides in rats of groups 2 and 3, but was significantly decreased on the side ipsilateral to 6‐OHDA striatal injection in rats of groups 1 and 4. These results show that subthalamic nucleus lesion provides neuroprotection of the dopaminergic nigrostriatal pathway against 6‐OHDA toxicity and opens a new way for slowing or stopping the progression of Parkinson's disease.
Url:
DOI: 10.1111/j.1460-9568.1996.tb01603.x
Links to Exploration step
ISTEX:DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title><author><name sortKey="Piallat, Brigitte" sort="Piallat, Brigitte" uniqKey="Piallat B" first="Brigitte" last="Piallat">Brigitte Piallat</name><affiliation><mods:affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</mods:affiliation></affiliation></author><author><name sortKey="Benazzouz, Abdelhamid" sort="Benazzouz, Abdelhamid" uniqKey="Benazzouz A" first="Abdelhamid" last="Benazzouz">Abdelhamid Benazzouz</name><affiliation><mods:affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</mods:affiliation></affiliation></author><author><name sortKey="Benabid, Alim Louis" sort="Benabid, Alim Louis" uniqKey="Benabid A" first="Alim Louis" last="Benabid">Alim Louis Benabid</name><affiliation><mods:affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1111/j.1460-9568.1996.tb01603.x</idno><idno type="url">https://api.istex.fr/document/DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003165</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title><author><name sortKey="Piallat, Brigitte" sort="Piallat, Brigitte" uniqKey="Piallat B" first="Brigitte" last="Piallat">Brigitte Piallat</name><affiliation><mods:affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</mods:affiliation></affiliation></author><author><name sortKey="Benazzouz, Abdelhamid" sort="Benazzouz, Abdelhamid" uniqKey="Benazzouz A" first="Abdelhamid" last="Benazzouz">Abdelhamid Benazzouz</name><affiliation><mods:affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</mods:affiliation></affiliation></author><author><name sortKey="Benabid, Alim Louis" sort="Benabid, Alim Louis" uniqKey="Benabid A" first="Alim Louis" last="Benabid">Alim Louis Benabid</name><affiliation><mods:affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neuroscience</title><idno type="ISSN">0953-816X</idno><idno type="eISSN">1460-9568</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1996-07">1996-07</date><biblScope unit="volume">8</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1408">1408</biblScope><biblScope unit="page" to="1414">1414</biblScope></imprint><idno type="ISSN">0953-816X</idno></series><idno type="istex">DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5</idno><idno type="DOI">10.1111/j.1460-9568.1996.tb01603.x</idno><idno type="ArticleID">EJN1408</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0953-816X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cell death</term><term>neuroprotection</term><term>substantia nigra</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Several studies have shown that antagonists of N‐methyl‐D‐aspartate receptors provide protection of the dopaminergic nigrostriatal pathway in animal models of Parkinson's disease. Since the substantia nigra compacta receives a moderate glutamatergic innervation from the subthalamic nucleus, we tried to determine whether subthalamic nucleus lesion could prevent the toxicity of the selective dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Experiments were carried out on four groups of rats. Group 1 (n= 10) received a unilateral injection of 6‐hydroxydopamine in the striatum and group 2 (n= 10) received kainic acid in the subthalamic nucleus. Group 3 (n= 10) received an injection of kainic acid in the subthalamic nucleus and 1 week later an injection of 6‐OHDA in the striatum. Group 4 (n= 5) received the same treatment but kainic acid was replaced by saline. Apomorphine induced an ipsilateral rotation in rats of groups 2 and 3 and a contralateral rotation in rats of groups 1 and 4. The number of tyrosine hydroxylase‐immunoreactive cells in the pars compacta of the substantia nigra was not significantly different between injected and non‐injected sides in rats of groups 2 and 3, but was significantly decreased on the side ipsilateral to 6‐OHDA striatal injection in rats of groups 1 and 4. These results show that subthalamic nucleus lesion provides neuroprotection of the dopaminergic nigrostriatal pathway against 6‐OHDA toxicity and opens a new way for slowing or stopping the progression of Parkinson's disease.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Brigitte Piallat</name><affiliations><json:string>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</json:string></affiliations></json:item><json:item><name>Abdelhamid Benazzouz</name><affiliations><json:string>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</json:string></affiliations></json:item><json:item><name>Alim Louis Benabid</name><affiliations><json:string>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>substantia nigra</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cell death</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><articleId><json:string>EJN1408</json:string></articleId><language><json:string>eng</json:string></language><abstract>Several studies have shown that antagonists of N‐methyl‐D‐aspartate receptors provide protection of the dopaminergic nigrostriatal pathway in animal models of Parkinson's disease. Since the substantia nigra compacta receives a moderate glutamatergic innervation from the subthalamic nucleus, we tried to determine whether subthalamic nucleus lesion could prevent the toxicity of the selective dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Experiments were carried out on four groups of rats. Group 1 (n= 10) received a unilateral injection of 6‐hydroxydopamine in the striatum and group 2 (n= 10) received kainic acid in the subthalamic nucleus. Group 3 (n= 10) received an injection of kainic acid in the subthalamic nucleus and 1 week later an injection of 6‐OHDA in the striatum. Group 4 (n= 5) received the same treatment but kainic acid was replaced by saline. Apomorphine induced an ipsilateral rotation in rats of groups 2 and 3 and a contralateral rotation in rats of groups 1 and 4. The number of tyrosine hydroxylase‐immunoreactive cells in the pars compacta of the substantia nigra was not significantly different between injected and non‐injected sides in rats of groups 2 and 3, but was significantly decreased on the side ipsilateral to 6‐OHDA striatal injection in rats of groups 1 and 4. These results show that subthalamic nucleus lesion provides neuroprotection of the dopaminergic nigrostriatal pathway against 6‐OHDA toxicity and opens a new way for slowing or stopping the progression of Parkinson's disease.</abstract><qualityIndicators><score>7.989</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1535</abstractCharCount><pdfWordCount>4705</pdfWordCount><pdfCharCount>29593</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>232</abstractWordCount></qualityIndicators><title>Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title><genre><json:string>article</json:string></genre><host><volume>8</volume><publisherId><json:string>EJN</json:string></publisherId><pages><total>7</total><last>1414</last><first>1408</first></pages><issn><json:string>0953-816X</json:string></issn><issue>7</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-9568</json:string></eissn><title>European Journal of Neuroscience</title><doi><json:string>10.1111/(ISSN)1460-9568</json:string></doi></host><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1111/j.1460-9568.1996.tb01603.x</json:string></doi><id>DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1996</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title><author><persName><forename type="first">Brigitte</forename><surname>Piallat</surname></persName><note type="correspondence"><p>Correspondence: B. Piallat, as above</p></note><affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</affiliation></author><author><persName><forename type="first">Abdelhamid</forename><surname>Benazzouz</surname></persName><affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</affiliation></author><author><persName><forename type="first">Alim Louis</forename><surname>Benabid</surname></persName><affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</affiliation></author></analytic><monogr><title level="j">European Journal of Neuroscience</title><idno type="pISSN">0953-816X</idno><idno type="eISSN">1460-9568</idno><idno type="DOI">10.1111/(ISSN)1460-9568</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1996-07"></date><biblScope unit="volume">8</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1408">1408</biblScope><biblScope unit="page" to="1414">1414</biblScope></imprint></monogr><idno type="istex">DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5</idno><idno type="DOI">10.1111/j.1460-9568.1996.tb01603.x</idno><idno type="ArticleID">EJN1408</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Several studies have shown that antagonists of N‐methyl‐D‐aspartate receptors provide protection of the dopaminergic nigrostriatal pathway in animal models of Parkinson's disease. Since the substantia nigra compacta receives a moderate glutamatergic innervation from the subthalamic nucleus, we tried to determine whether subthalamic nucleus lesion could prevent the toxicity of the selective dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Experiments were carried out on four groups of rats. Group 1 (n= 10) received a unilateral injection of 6‐hydroxydopamine in the striatum and group 2 (n= 10) received kainic acid in the subthalamic nucleus. Group 3 (n= 10) received an injection of kainic acid in the subthalamic nucleus and 1 week later an injection of 6‐OHDA in the striatum. Group 4 (n= 5) received the same treatment but kainic acid was replaced by saline. Apomorphine induced an ipsilateral rotation in rats of groups 2 and 3 and a contralateral rotation in rats of groups 1 and 4. The number of tyrosine hydroxylase‐immunoreactive cells in the pars compacta of the substantia nigra was not significantly different between injected and non‐injected sides in rats of groups 2 and 3, but was significantly decreased on the side ipsilateral to 6‐OHDA striatal injection in rats of groups 1 and 4. These results show that subthalamic nucleus lesion provides neuroprotection of the dopaminergic nigrostriatal pathway against 6‐OHDA toxicity and opens a new way for slowing or stopping the progression of Parkinson's disease.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>substantia nigra</term></item><item><term>cell death</term></item><item><term>neuroprotection</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1460-9568</doi><issn type="print">0953-816X</issn><issn type="electronic">1460-9568</issn><idGroup><id type="product" value="EJN"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROSCIENCE">European Journal of Neuroscience</title></titleGroup></publicationMeta><publicationMeta level="part" position="07007"><doi origin="wiley">10.1111/ejn.1996.8.issue-7</doi><numberingGroup><numbering type="journalVolume" number="8">8</numbering><numbering type="journalIssue" number="7">7</numbering></numberingGroup><coverDate startDate="1996-07">July 1996</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0140800" status="forIssue"><doi origin="wiley">10.1111/j.1460-9568.1996.tb01603.x</doi><idGroup><id type="unit" value="EJN1408"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><eventGroup><event type="firstOnline" date="2006-04-07"></event><event type="publishedOnlineFinalForm" date="2006-04-07"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-12"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1408">1408</numbering><numbering type="pageLast" number="1414">1414</numbering></numberingGroup><correspondenceTo>B. Piallat, as above</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:EJN.EJN1408.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 31 July 1995, revised 29 January 1996, accepted 5 February 1996</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="40"></count><count type="linksCrossRef" number="4"></count></countGroup><titleGroup><title type="main">Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Brigitte</givenNames><familyName>Piallat</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Abdelhamid</givenNames><familyName>Benazzouz</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Alim Louis</givenNames><familyName>Benabid</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">substantia nigra</keyword><keyword xml:id="k2">cell death</keyword><keyword xml:id="k3">neuroprotection</keyword><keyword xml:id="k4">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Several studies have shown that antagonists of <i>N</i>‐methyl‐D‐aspartate receptors provide protection of the dopaminergic nigrostriatal pathway in animal models of Parkinson's disease. Since the substantia nigra compacta receives a moderate glutamatergic innervation from the subthalamic nucleus, we tried to determine whether subthalamic nucleus lesion could prevent the toxicity of the selective dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Experiments were carried out on four groups of rats. Group 1 (<i>n</i>= 10) received a unilateral injection of 6‐hydroxydopamine in the striatum and group 2 (<i>n</i>= 10) received kainic acid in the subthalamic nucleus. Group 3 (<i>n</i>= 10) received an injection of kainic acid in the subthalamic nucleus and 1 week later an injection of 6‐OHDA in the striatum. Group 4 (<i>n</i>= 5) received the same treatment but kainic acid was replaced by saline. Apomorphine induced an ipsilateral rotation in rats of groups 2 and 3 and a contralateral rotation in rats of groups 1 and 4. The number of tyrosine hydroxylase‐immunoreactive cells in the pars compacta of the substantia nigra was not significantly different between injected and non‐injected sides in rats of groups 2 and 3, but was significantly decreased on the side ipsilateral to 6‐OHDA striatal injection in rats of groups 1 and 4. These results show that subthalamic nucleus lesion provides neuroprotection of the dopaminergic nigrostriatal pathway against 6‐OHDA toxicity and opens a new way for slowing or stopping the progression of Parkinson's disease.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies</title></titleInfo><name type="personal"><namePart type="given">Brigitte</namePart><namePart type="family">Piallat</namePart><affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</affiliation><description>Correspondence: B. Piallat, as above</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Abdelhamid</namePart><namePart type="family">Benazzouz</namePart><affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alim Louis</namePart><namePart type="family">Benabid</namePart><affiliation>Laboratoire de Neurobiologie Préclinique, INSERM U.318, CHU, Pavillon B, BP 217, 38043 Grenoble Cedex 09, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1996-07</dateIssued><edition>Received 31 July 1995, revised 29 January 1996, accepted 5 February 1996</edition><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">40</extent></physicalDescription><abstract lang="en">Several studies have shown that antagonists of N‐methyl‐D‐aspartate receptors provide protection of the dopaminergic nigrostriatal pathway in animal models of Parkinson's disease. Since the substantia nigra compacta receives a moderate glutamatergic innervation from the subthalamic nucleus, we tried to determine whether subthalamic nucleus lesion could prevent the toxicity of the selective dopaminergic neurotoxin 6‐hydroxydopamine (6‐OHDA). Experiments were carried out on four groups of rats. Group 1 (n= 10) received a unilateral injection of 6‐hydroxydopamine in the striatum and group 2 (n= 10) received kainic acid in the subthalamic nucleus. Group 3 (n= 10) received an injection of kainic acid in the subthalamic nucleus and 1 week later an injection of 6‐OHDA in the striatum. Group 4 (n= 5) received the same treatment but kainic acid was replaced by saline. Apomorphine induced an ipsilateral rotation in rats of groups 2 and 3 and a contralateral rotation in rats of groups 1 and 4. The number of tyrosine hydroxylase‐immunoreactive cells in the pars compacta of the substantia nigra was not significantly different between injected and non‐injected sides in rats of groups 2 and 3, but was significantly decreased on the side ipsilateral to 6‐OHDA striatal injection in rats of groups 1 and 4. These results show that subthalamic nucleus lesion provides neuroprotection of the dopaminergic nigrostriatal pathway against 6‐OHDA toxicity and opens a new way for slowing or stopping the progression of Parkinson's disease.</abstract><subject lang="en"><genre>Keywords</genre><topic>substantia nigra</topic><topic>cell death</topic><topic>neuroprotection</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neuroscience</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0953-816X</identifier><identifier type="eISSN">1460-9568</identifier><identifier type="DOI">10.1111/(ISSN)1460-9568</identifier><identifier type="PublisherID">EJN</identifier><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1408</start><end>1414</end><total>7</total></extent></part></relatedItem><identifier type="istex">DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5</identifier><identifier type="DOI">10.1111/j.1460-9568.1996.tb01603.x</identifier><identifier type="ArticleID">EJN1408</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003165 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 003165 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:DCFAC59007BA9B17DB0CC3E22F6A46001793F2C5
|texte= Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies
}}
| This area was generated with Dilib version V0.6.23. |  |